Blackford has entered a commercial partnership with Lucida Medical to integrate Lucida's prostate cancer MRI imaging software (Pi) into its AI platform.
Pi is designed to help healthcare professionals work more quickly by automating laborious steps and increasing accuracy for MRI detection of clinically significant prostate cancer. The software has proven effective in supporting analysis of prostate MRIs in real-world applications across multiple healthcare settings, scanner types, and vendors, Blackford said.
Lucida Medical is a spin-off company out of Cambridge University in England. Blackford’s AI platform provides access to more than 120 AI products designed to drive clinical efficiencies and improve patient outcomes, the company noted.
